Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Eric Schmidt reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Overweight.
Di Donato has accepted the role of Chief Executive Officer at a private, early-stage biotech headquartered in San Diego, Califo...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $100 pri...
Oppenheimer analyst Jeff Jones reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Outperform and raises the price target from ...
Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $81 price target.
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0....
